Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Computational and Mathematical Methods in Medicine|August 9, 2017
Pathway-Based Kernel Boosting for the Analysis of Genome-Wide Association StudiesStefanie Friedrichs, Juliane Manitz, Patricia Burger, et al.
Journal for Immunotherapy of Cancer|November 21, 2020
Efficacy and immune-related adverse event associations in avelumab-treated patientsKaren Kelly, Juliane Manitz, Manish R Patel, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 31, 2021
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumabNadia Terranova, Jonathan French, Haiqing Dai, et al.
Drug Discovery Today|January 23, 2026
The statistical software revolution in pharmaceutical development: challenges and opportunities in open sourceDaniel Sabanés Bové, Heidi Seibold, Anne-Laure Boulesteix, et al.
Future Oncology (London, England)|February 11, 2022
Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid TumorBorys Hrinczenko, Nicholas Iannotti, Sanjay Goel, et al.
Pharmaceutical Statistics|October 4, 2021
Estimands for overall survival in clinical trials with treatment switching in oncologyJuliane Manitz, Natalia Kan-Dobrosky, Hannes Buchner, et al.
European Urology Oncology|May 3, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 TrialPetros Grivas, Jeanny B Aragon-Ching, Joaquim Bellmunt, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysisAndrea B Apolo, John A Ellerton, Jeffrey R Infante, et al.
The Journal of Urology|June 20, 2020
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 InhibitorsGuru Sonpavde, Juliane Manitz, Chen Gao, et al.
Pageof 2